BUND FINANCE › Stocks › HLN
Haleon plc (HLN)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -2.64% below its 50-day average.
- It is -6.33% below its 200-day average (long-term downtrend).
- It sits at 24% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | GBP 9.5B | GBP 10.9B | GBP 11.3B | GBP 11.2B | GBP 11.0B |
| Net income | GBP 1.4B | GBP 1.1B | GBP 1.0B | GBP 1.4B | GBP 1.7B |
| EPS (diluted) | 0.30 | 0.24 | 0.24 | 0.32 | 0.37 |
| Gross margin | 62.3% | 60.6% | 61.6% | 61.9% | 64.2% |
| Operating margin | 17.2% | 16.8% | 17.7% | 19.6% | 21.9% |
| Net margin | 14.6% | 9.8% | 9.3% | 12.8% | 15.1% |
| Free cash flow | GBP 1.1B | GBP 1.7B | GBP 1.8B | GBP 2.1B | GBP 2.3B |
| Total debt | GBP 991.0M | GBP 10.4B | GBP 9.5B | GBP 10.1B | GBP 8.6B |
| Cash | GBP 414.0M | GBP 684.0M | GBP 1.0B | GBP 2.3B | GBP 1.3B |
Compound annual growth: revenue 3.7% · net income 4.7% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 23.5x | 27.1x |
| EV / EBITDA | — | 15.4x | 16.5x |
| Operating margin | 22.7% | — | 3.6% |
| Net margin | 14.6% | — | -0.0% |
| Debt / equity | 0.99 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.
About Haleon plc
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice